Reckitt Benckiser (RB), the company behind such household names as Durex, Cillit Bang and Nurofen, is in talks to buy a baby formula manufacturer for $16.7bn (£13.2bn).
In a statement this morning, RB said it was in advanced talks with Mead Johnson to buy its shares at $90 each, valuing it at $16.7bn.
The company said it will finance the transaction through a combination of cash and debt - but assured shareholders it will retain a "strong investment grade credit rating" throughout.
Investors were clearly convinced: shares in RB rose 3.6 per cent to 7,077p as the market opened this morning. Meanwhile, Mead Johnson's shares leaped 23.74 per cent to $86 in after-hours trading in New York.
RB hit the headlines at the end of last year when it was handed a £3.5m fine by an Australian court over claims it misled customers by claiming its Nurofen products targeted specific parts of the body.
A year earlier, the UK's Advertising Standards Authority (ASA) said it had launched an investigation into Nurofen Express over claims it can directly target muscles in the head.